<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855177</url>
  </required_header>
  <id_info>
    <org_study_id>B7871005</org_study_id>
    <nct_id>NCT02855177</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary
      purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2
      weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2016</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Day -2 to Day 44</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory tests</measure>
    <time_frame>Day 1 to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Day 0 to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in cardiac conduction intervals assessed via 12-lead electrocardiogram</measure>
    <time_frame>Day 0 to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06427878 on day 1</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06427878 on day 1</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for PF-06427878 during the dosing interval (AUCtau) on day 1</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for PF-06427878 during the dosing interval (AUCtau) on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) for PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak:Trough ratio of PF-06427878 on day 14</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUCtau)) for PF-06427878 on day 14 relative to day 1</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06427878 on day 14 relative to day 1</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of PF-06427878 excreted in urine (Ae) on day 14</measure>
    <time_frame>0-8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of dose excreted in urine as PF-06427878 (Ae%) on day 14</measure>
    <time_frame>0-8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of PF-06427878 (CLr) on day 14</measure>
    <time_frame>0-8 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06427878</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo as suspension administered every 8 hours, with food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06427878</intervention_name>
    <description>500 mg suspension administered every 8 hours, with food</description>
    <arm_group_label>PF-06427878</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non childbearing potential.

          -  Body Mass Index (BMI) of &gt;=25 kg/m2; and a total body weight &gt;50 kg

          -  Subjects with liver fat &gt;=6% and &lt;=20%

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary,gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7871005&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Parallel-group+Study+To+Assess+The+Safety%2C+Tolerability%2C+And+Pharmacokinetics+With+2-weeks+Of+Dosing+Of+Pf-06427878+In+Overweight-obese%2C+Otherwise+Healthy+Adult+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

